Krystal Biotech's $400 million buyback leaves growth test intact. Krystal Biotech's earnings beat and open-ended buyback sharpen the focus on VYJUVEK expansion, pipeline spending and divergent 2029 profit forecasts. Key facts. * Quarterly earnings: Q3 2026 net income of US$63.07 million; diluted EPS of US$2.05. * Share repurchases: US$400 million authorization with no expiration date. * VYJUVEK growth: Revenue increased 30% year over year. * Stock performance: KRYS gained 1.96% intraday as of November 3, 2026, at 15:21:22 GMT. Krystal Biotech authorized a US$400 million share repurchase program after reporting third-quarter 2026 net income of US$63.07 million and 30% year-over-year VYJUVEK revenue growth. Krystal Biotech (KRYS) has added a US$400 million share repurchase authorization to an investment case still driven by VYJUVEK sales and the cost of developing additional therapies. The authorization has no expiration date, giving management discretion over when to buy shares rather than committing it to a fixed spending timetable. The company reported third-quarter 2026 net income of US$63.07 million and diluted earnings per share of US$2.05, beating consensus estimates for both earnings and revenue, according to Yahoo Finance. VYJUVEK revenue increased 30% from a year earlier. Shares were up 1.96% in intraday trading as of November 3 at 15:21:22 GMT. The earnings results and repurchase plan give investors more to assess, but neither eliminates the need for continued commercial growth. A flexible buyback alongside expansion costs. The distinction between an authorization and completed purchases matters here. The US$400 million program allows Krystal to return capital through repurchases; it does not establish how much the company will spend immediately or when the full amount might be used. That flexibility is relevant because Krystal is funding both international commercialization and a broader gene-therapy pipeline. Spending on KB803, KB801, KB707 and other projects must compete for capital with share purchases. A program without an expiration date leaves room to adjust that balance as development and commercial needs change. Spending on KB803, KB801, KB707 and other projects must compete for capital with share purchases. VYJUVEK's 30% revenue growth supports the company's ability to pursue those priorities. The next commercial test is converting international expansion into sustained sales, with European pricing progress and execution in Europe and Japan central to that effort. Pricing progress is important, but its investment value ultimately depends on the revenue and profit that follow. Profit forecasts expose the longer-term divide. The range of expectations for 2029 illustrates why an earnings beat alone cannot settle Krystal's valuation debate. The consensus outlook cited in the report projects revenue of US$1.3 billion and earnings of US$772.0 million. The most bearish analysts instead modeled roughly US$841.0 million in revenue and about US$307.6 million in earnings for 2029. Those estimates preceded the latest update and should be treated as forecasts, not company commitments or settled outcomes. The disagreement concerns both the scale of future sales and how much profit those sales can produce. Repurchases can reduce the share count if executed, but they cannot substitute for product demand or control the expense of expanding development programs. Pipeline breadth adds opportunity and spending demands. Early KB113 data in Gorlin syndrome added another potential growth avenue beyond VYJUVEK. At the same time, timing shifts in other programs underline that pipeline progress will not necessarily follow a uniform schedule. Krystal's quarter therefore strengthens the current commercial foundation without resolving the longer-term spending question. The buyback adds capital-allocation flexibility; international sales execution and the pace of pipeline investment remain the factors most directly connected to achieving the more ambitious profit forecasts.

Krystal Biotech beat consensus on earnings and revenue in the third quarter of 2026, reporting net income of $63.07 million and diluted earnings per share of $2.05. The company also announced a new $400 million share repurchase programme with no expiration date. Sales of its skin disease gene therapy VYJUVEK rose 30% year on year, helped by progress on European pricing. Early data for KB113 in Gorlin syndrome added depth to its pipeline, though timing shifted for some other programmes. Analysts' consensus expects 2029 revenue of $1.3 billion and earnings of $772.0 million. The most bearish forecasts see earnings of about $307.6 million on roughly $841.0 million of revenue.